FDA Approves Unknown Drug — AMNEAL PHARMS NY

Amneal Pharmaceuticals announced FDA approval of its Abbreviated New Drug Application number ANDA206869 on June 23, 2017, subjecting the drug to significant pricing pressures. This generic entry disrupts the market landscape, compressing the profit margins of brand-name competitors present in the relevant therapeutic class.